assume risk-adj. peak sales of $1.5bn in 2029 with $604mn in DS, $503mn in LGS, $386mn in other pediatric epilepsies. Based on positive feedback from physicians and high unmet need, we assume 60% peak penetration in DS, 20% in LGS and 7.5% in other pediat

assume risk-adj. peak sales of $1.5bn in 2029 with $604mn in DS, $503mn in LGS, $386mn in other pediatric epilepsies. Based on positive feedback from physicians and high unmet need, we assume 60% peak penetration in DS, 20% in LGS and 7.5% in other pediatric epilepsie

More From BioPortfolio on "assume risk-adj. peak sales of $1.5bn in 2029 with $604mn in DS, $503mn in LGS, $386mn in other pediatric epilepsies. Based on positive feedback from physicians and high unmet need, we assume 60% peak penetration in DS, 20% in LGS and 7.5% in other pediat"